Phase 2a clinical trial for Crohn disease using adrenomedullin

Effects of adrenomedullin in biologics-resistant patients with Crohn disease: randomized, double-blind, placebo-controlled phase 2a clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223890

Enrollment

Registered

2018-05-02

Start date

2018-05-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn disease

Interventions

investigational material(s) Generic name etc : adrenomedullin INN of investigational material : adrenomedullin Therapeutic category code : 249 Other hormone preparations (including antihormone prepara

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Biologics-resistant patients against maintenance therapy of biologics

Exclusion criteria

Exclusion criteria: Non-responder for biologics Patients with small intestinal lesion and having risk of ileus Patient with fulminant Crohn disease(CD) Patient need early operation for CD Patient with active infection Patient with severe complication(s) Patient with malignancy or past history of malignancy Pregnant woman

Design outcomes

Primary

Measure	Time frame
efficacy change of CDAI at week 8	—

Secondary

Measure	Time frame
safety efficacy change of CDAIat week 4 and 6 effective rate of CDAI at week 8 endoscopic evaluation (SESCD) at week 8 change of CRP at week 4 and 8 fecal immunochemical test and calprotectin at week 1	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026